Report: Supreme Court rejects Mylan appeal

NEW YORK — Mylan may have to pay $77 million to four health insurers over allegations that it sought to control the market on ingredients used for two anti-anxiety medicines, according to published reports.

Bloomberg reported that the Supreme Court rejected the drug maker's appeal of a 2005 jury verdict in a case that involved antitrust allegations regarding the drugs lorazepam and clorazepate.

The news agency reported that Mylan had argued that federal courts lacked authority to consider the case, and that an appeals court had told a trial judge to cut the award down instead of dismissing the suit. The article noted that the company has faced antitrust allegations concerning the drugs since 2000, with the Federal Trade Commission complaining that exclusive supply agreements allowed Mylan to raise the price of the drugs by more than 2,500%.

Mylan did not respond to a Drug Store News request for comment.

Interested in this topic? Sign up for our weekly Retail Health Provider e-newsletter.